greeksoup/ stock research
Stock research / United States / STLN / Documents

Starling Oncology, Inc. documents

Starling Oncology (STLN) annual report: the 10-K filed 12 March 2026 for the year ended 31 December 2025. Proxy statement (DEF 14A) filed 30 April 2026; latest 10-Q filed 6 August 2026 for the quarter ended 30 June 2026. Each links to the document on EDGAR, with 5 earnings press releases.

Earnings press releases (exhibit 99 to each results 8-K)

FiledDocumentOpenWhere
6 August 2026Results press release, exhibit 99 to the 8-K filed 6 August 2026The releaseEDGAR folder
7 May 2026Results press release, exhibit 99 to the 8-K filed 7 May 2026The releaseEDGAR folder
12 March 2026Results press release, exhibit 99 to the 8-K filed 12 March 2026The releaseEDGAR folder
12 January 2026Results press release, exhibit 99 to the 8-K filed 12 January 2026The releaseEDGAR folder
13 November 2025Results press release, exhibit 99 to the 8-K filed 13 November 2025The releaseEDGAR folder

Annual reports (10-K)

FiledDocumentOpenWhere
12 March 202610-K, period ended 31 December 2025The documentEDGAR folder

Quarterly reports (10-Q)

FiledDocumentOpenWhere
6 August 202610-Q, period ended 30 June 2026The documentEDGAR folder
7 May 202610-Q, period ended 31 March 2026The documentEDGAR folder
13 November 202510-Q, period ended 30 September 2025The documentEDGAR folder

Proxy statements

FiledDocumentOpenWhere
30 April 2026DEF 14A, period ended 17 June 2026The documentEDGAR folder

Annual report to shareholders

FiledDocumentOpenWhere
28 April 2026ARS, period ended 31 December 2025The documentEDGAR folder